Viridian Therapeutics, Inc.\DE(VRDN)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Viridian Therapeutics, Inc.\DE (VRDN) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores VRDN at 27.2/100 on a 32-signal composite quality model, placing it at rank #2,588 of 2,960 stocks — the bottom half of the AI-ranked universe. VRDN scores in the top quartile across revenue growth (99.3). Areas of concern include free cash flow (2.8) and profitability (3.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 4.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Viridian Therapeutics, Inc.\DE reports quarterly revenue of $284.0K, net income of $-127.1M, free cash flow of $-106.6M. Top institutional holders of VRDN by reported 13-F value include FMR, BlackRock, Bellevue Group AG, based on the most recent SEC filings. VRDN trades on the Nasdaq exchange and files with the SEC under CIK 1590750. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate VRDN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Viridian Therapeutics, Inc.\DE directly from SEC EDGAR.